Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Study to Compare Effectiveness, Safety and Costs of Rivaroxaban Versus Warfarin Treatment in Morbidly Obese Patients with Venous Thromboembolism

Next Previous
Search
Trial Profile

A Retrospective Study to Compare Effectiveness, Safety and Costs of Rivaroxaban Versus Warfarin Treatment in Morbidly Obese Patients with Venous Thromboembolism

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Venous thromboembolism
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Sep 2019 New trial record
    • 20 Sep 2019 Primary endpoint (The risk of recurrent VTE, defined as a hospitalization or ER visit with a primary diagnosis of VTE during the follow-up period: XARELTO versus warfarin) has not been met, according to a Janssen Pharmaceuticals media release.
    • 20 Sep 2019 According to a Janssen Pharmaceuticals media release, results of this study were recently published in Thrombosis Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top